MAVENCLAD cpr 10 mg
7680668310012
CH-66831
L04AA40
01.99.0.
Reimbursement limitations:
MAVENCLAD_2
Mavenclad est indiqué chez les adultes dans le traitement des formes très actives de sclérose …
1 / 3
google
Details
- Product number
- 6683101
- CPT
- -
- Packaging group
- 1
- Unit
- Tablette(n)
- Composition
- cladribinum 10.00 mg, hydroxypropylbetadexum, sorbitolum 64.04 mg, magnesii stearas, pro compresso.
Articles (1)
Mavenclad 10 mg, Tabletten
Tabletten
1
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
10.0 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
64.04 MG | Substance | HBESI |
|
(N/A)
|
- | Substance | HNIDK |
Reimbursement information
Public price
CHF 2570.20
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/06/2019
Authorization holder
Merck (Schweiz) AG
6300 Zug
Authorization information
- Swissmedic authorization number
- 66831
- Drug name
- Mavenclad, Tabletten
- Galenic form
- TAB
- ATC Code
- L04AA40
- Authorization status
- Z
- Dispensation category
- A
- First authorization
- 19/03/2019
- Authorization expiration date
- 31/12/9999
- IT number
- 01.99.0.
- Domain
- Human medicine
Packaging details
- Description (FR)
- MAVENCLAD cpr 10 mg
- Description (DE)
- MAVENCLAD Tabl 10 mg
- Market launch
- 19/03/2019
- Narcotic (BTM)
- No